Floriano-Sánchez E, Torres-Salazar JJ, Cárdenas-Rodríguez N, Castro-Marín M, López-Silvestre J, Zapata-Villalba MA, Flores-Terrazas JE

Language: Spanish
References: 20
Page: 341-346
PDF size: 1138.22 Kb.

ABSTRACT

Background: Due to the elevated incidence of prostate cancer in the Mexican population, it is of the utmost importance to contribute to the formulation of hypotheses resulting in studies that increase the probability of developing cancer-diagnosing molecular markers. The present study evaluates possible alterations in inducible nitric oxide synthase, an oxidative stress marker, in prostate cancer and benign prostatic hyperplasia.
Methods: Thirty-nine benign prostatic hyperplasia samples and forty-two prostate cancer samples were obtained and conditions were standardized to immunohistochemically detect the presence of inducible nitric oxide synthase in the tissues.
Results: Inducible nitric oxide synthase immunoreactivity area percentage was 15.89 ± 7.1% in prostate cancer tissue and 23.2 ± 8.8% in benign prostatic hyperplasia tissue.
Conclusions: Densitometric data of inducible nitric oxide synthase immunoreactivity in prostate cancer glandular tissue were lower than those obtained in similar benign prostatic hyperplasia tissue, suggesting that inducible nitric oxide synthase determination could be used as an oncogenic marker.

REFERENCES

1. Hall SE, Holman CD, Wisniewski ZS. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int 2005;95:51-8.

2. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. Boca Raton, Flo. CRC Press, 1997.

3. Manual de Oncología. Instituto Nacional de Cancerología. México. McGrawHill, 2003.

4. Guess HA. Benign prostatic Hyperplasia: antecedents and natural history. Epidemiol Rev 1992;14:131-53.

5. Thorpe A, Neal D. Benign Prostatic Hyperplasia. Lancet 2003;361:1359-67.

6. Sarmina Y, Resnick MI. Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989;141:866-9.

7. Barry M. Epidemiology and natural history of benign prostatic hyperplasia. Raven Press, 1994.

8. De Marzo A. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998;160(6 Pt 2):2381-92.

9. Hennekens CH. Antioxidant Vitamins and Cancer. Am J Med 1994;97(3A):2S-4S.

10. Moodley YP. The role of inducible nitric oxide in health and disease. Current Diagnostic Pathology 2002;8:297-304.

11. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004;75:639-53.

12. Hurtado BF. Estrés oxidativo y nitrosativo en la sepsis. Medicina Intensiva 2005;29:159-65.

13. Sánchez GD. Expresión de las sintasas de óxido nítrico en tumores glómicos de cabeza y cuello. Rev Sanid Milit Mex 2006;60:369-78.

14. Masri FA, Comhair SA, Koeck T. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 2005;172:597-605.

15. Oberley TD. Oxidative Damage and Cancer. Am J Pathol 2002;160:403-8.

16. Klotz T, Bloch W, Volberg C. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998;82:1897-903.

17. Marangoni K, Neves AF, Cardoso AM Endotelial nitric oxide synthase (eNOS) and mRNA expression in periferical blood of patients with prostate cancer and benign prostate hyperplasia. Cancer Detect Prev 2006;30:7-13.

18. Díaz AD. Oxido nítrico, mutagénesis y cáncer. Rev Revista Cubana de Investigación Biomédica 2004;23:184-89.

19. Cronauer MV, Ince Y, Engers R Nitric oxide mediated inhibition of androgen recerptor activity; possible implications for prostate cancer progression. Oncogene 2007;26:1875-84.

20. Baltaci S, Orhan D, Gögüs C Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low and high grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2001;88:100-3.